Seeking Alpha

OPKO Health, Inc. (OPK)

  • Mon, Apr. 6, 11:04 AM
    • MabVax Therapeutics Holdings (OTCQB:MBVX +28.3%) closes $11.6M in new financing via a private placement led by OPKO Health (OPK -0.2%) and its Chairman & CEO Dr. Philip Frost. The company issued 15,486,001 units at $0.75 per unit for net proceeds of ~$11.1M. Each unit consists of one share of common stock and a 30-month warrant to purchase one-half share of common stock at $1.50.
    • Net proceeds will fund the advancement of novel human antibodies in its pipeline, including the initiation of a Phase 1 trial of its lead antibody, HuMab 5B1.
    | Comment!
  • Thu, Mar. 5, 4:35 PM
    • Thinly-traded small cap Heron Therapeutics (NASDAQ:HRTX) heads north again delivering another 10% on an 8x surge in volume. Shares have more than doubled since the intermediate low of $7.09 on January 22.
    • The party kicked into high gear in early February when the company announced the initiation of a Phase 1 trial evaluating the safety, pharmacokinetics and pharmacodynamics of HTX-011, an investigational pain medicine the utilizes the company's Biochronomer polymer-based drug delivery platform to release the local anesthetic bupivacaine and the nonsteroidal anti-inflammatory drug (NSAID) meloxicam over an extended period. HTX-011 has previously shown to significantly reduce pain in a validated animal model for up to 72 hours following surgery, although exactly how this was measured is unclear. The company expects to report the results this quarter. A series of Phase 1b/2 trials is on tap to begin in Q2 assessing HTX-011 in a post-surgical pain setting with results expected before the end of the year.
    • The company's lead product candidate is the Phase 3-stage Sustol (granisetron injection, extended release) for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV). Granisetron is a 5-HT3 receptor antagonist also formulated in the Biochronomer drug delivery platform. The FDA has approved only one 5-HT3 receptor antagonist to date, GlaxoSmithKline's Zofran (ondansetron hydrochloride) injection in 1991.
    • CINV-related tickers: (NYSE:OPK) (NASDAQ:INSY) (NASDAQ:TSRO)
    | Comment!
  • Thu, Feb. 5, 3:23 PM
    • The resignation of prominent healthcare investor/entrepreneur Dr. Phillip Frost, M.D., from Teva Pharmaceutical Industries' (TEVA +1.8%) Board of Directors prompts aggressive buying from speculators who think a potential deal is afoot with Opko Health (OPK +4.6%). Teva is up on 50% higher volume while Opko's turnover is 3x average.
  • Dec. 15, 2014, 9:12 AM
    | 1 Comment
  • Dec. 15, 2014, 8:56 AM
    • Opko Health (NYSE:OPK) is up 14% premarket on robust volume in response to its deal with Pfizer (NYSE:PFE). The latter will be pay Opko an upfront fee of $295M and up to $275M in regulatory milestones for the global rights to hGH-CTP, a long-acting growth hormone. Its value proposition is a once-weekly injection, a significant improvement over the once-daily standard of care.
    • Opko acquired the rights to hGH-CTP via its takeout of Israel-based Prolor last year.
    • Previously: Opko completes its acquisition of Prolor Biotech (Aug. 29, 2013)
  • May. 12, 2014, 9:09 AM
    • Tesaro's (TSRO) Rolapitant drug for the prevention of chemotherapy-induced nausea and vomiting (CINV) has met the primary and secondary goals of a Phase III study of 532 cancer patients, achieving statistical significance compared with standard treatments.
    • The data adds to the positive results of two other late-stage trials, the results of which Tesaro announced in December.
    • Tesaro plans to apply for FDA approval of Rolapitant in mid-2014; the treatment would compete with Merck's Emend.
    • The company's shares are +18.7%, while those of Opko Health (OPK), which sold Tesaro rights to Rolapitant for as much as $121M in up-front and milestone payments, are +0.5%. (PR)
    | Comment!
  • Feb. 13, 2014, 5:43 PM
  • Dec. 18, 2013, 10:42 AM
    • Jefferies is out with some commentary on Opko Health (OPK +5.2%) amid controversy surrounding a short thesis advanced by Lakewood Capital (see Lakewood's article on SA here).
    • "In our view, timely achievements of its laid-out milestones and future sales revenues meeting our expectations (albeit significantly lower than its noted market opportunities) would likely provide potential upside to current levels," analyst Eun Yang says.
    • Buy rating reiterated.
    • Price target is $11.50.
  • Dec. 16, 2013, 9:11 AM
  • Dec. 13, 2013, 12:51 PM
  • Dec. 12, 2013, 5:34 PM
    • Top gainers, as of 5:15 p.m.: ADBE +6.2%. NQ +5.6%. GCAP +5.3%. DXYN +4.3%. OPK +4.2%.
    • Top losers, as of 5:15 p.m.: RH -12.5%. APC -9.9%. CETV -6.4%. AMBI -5.2%. HYGS -4.9%.
  • Dec. 6, 2013, 9:09 AM
    • Opko Health (OPK) trades 2% higher before the bell.
    • Helping the cause is SA contributor John Ford, who says Rayaldy "should be a blockbuster."
    • "What will Rayaldy be worth in two years?" Ford asks, before saying that in his estimation, the total market potential is $16-24B annually.
  • Nov. 21, 2013, 2:18 PM
    • Shares of Opko Health (OPK -5.4%) abruptly turn red after rallying earlier in the session.
    • Chatter suggests Lakewood Capital's Anthony Bozza has disclosed a short position.
    • Bozza spoke today at the Robin Hood Investors Conference Lightning Round.
  • Aug. 30, 2013, 5:34 PM
    | 1 Comment
  • Jun. 18, 2013, 5:48 PM
    After-hours top gainers, as of 5:15 p.m.: CO +6%. ADBE +4%. OPK +3%. MY +3%. GEVO +2%.
    After-hours top losers: TTEK -12%. POOL -7%. MGI -5%. AAWW -4%. CROX -3%.
    | 1 Comment
  • Apr. 24, 2013, 9:08 AM
    Prolor Biotech (PBTH), will be acquired by OPKO Health (OPK) in an all-stock deal worth $480M. PBTH shareholders will get 0.9551 shares of OPK for every share of PBTH they own, equating to $7 per share as of Tuesday's closing prices. PBTH +10.65% premarket. (Previously: strategic alternative evaluation boosts Prolor)
Visit Seeking Alpha's
OPK vs. ETF Alternatives
Company Description
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.